Bioverativ Inc (NASDAQ:BIVV) Director Louis J. Paglia acquired 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The shares were bought at an average cost of $59.70 per share, with a total value of $119,400.00. Following the completion of the purchase, the director now owns 5,056 shares of the company’s stock, valued at $301,843.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Bioverativ Inc (NASDAQ:BIVV) opened at 55.05 on Friday. The firm has a market cap of $5.96 billion and a P/E ratio of 13.09. The firm’s 50-day moving average price is $60.48 and its 200-day moving average price is $55.53. Bioverativ Inc has a 12 month low of $40.00 and a 12 month high of $64.41.
Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.88 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.17. The company had revenue of $289.10 million for the quarter, compared to the consensus estimate of $269 million. The firm’s revenue for the quarter was up 37.5% on a year-over-year basis. During the same quarter last year, the company earned $0.59 EPS. On average, equities research analysts expect that Bioverativ Inc will post $2.92 EPS for the current fiscal year.
BIVV has been the topic of several recent analyst reports. Credit Suisse Group lifted their target price on Bioverativ from $45.00 to $47.00 and gave the stock an “underperform” rating in a report on Monday, May 15th. Jefferies Group LLC restated a “buy” rating and issued a $70.00 price target (up from $67.00) on shares of Bioverativ in a report on Wednesday, August 9th. Gabelli lowered Bioverativ from a “buy” rating to a “hold” rating in a report on Monday, April 24th. They noted that the move was a valuation call. Zacks Investment Research upgraded Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 price target on the stock in a report on Tuesday, July 25th. Finally, William Blair began coverage on Bioverativ in a report on Wednesday, June 28th. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Bioverativ has a consensus rating of “Hold” and a consensus target price of $60.43.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.